Inovio Pharmaceuticals (INO) announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia …
In a research report issued yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Inovio Pharmaceuticals (INO) with an $18 price target, …
In a report published today, Maxim analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals, Inc. (INO) with an adjusted price target of $18.
